Uganda Virus Research Institute
Rakai, Uganda
NCT Number: NCT00342160
This study will look at viral and immunologic factors involved in protecting against sexually transmitted HIV infection in couples in which one partner is infected and the other is not.
This study will include 50 couples who reside in Rakai, Uganda, and who have been together for at least 2 years. In some couples, both partners will be HIV-infected, in some couples only one partner will have HIV, and in some couples neither partner will have HIV.
Participants undergo the following procedures at each of four study visits:
* HIV counseling and testing * Medical history, including questions about personal behaviors such as sexual practices and use of condoms * Blood sample collection * Urine sample collection * Vaginal swab for women
Blood, urine and vaginal fluid samples are tested for HIV and other sexually transmitted diseases, such as syphilis. Blood and vaginal samples are also tested for HIV viral levels and immune response in HIV-infected individuals and for evidence of exposure to HIV in non-infected participants. Some blood is also tested for genetic markers to investigate whether certain proteins are related to resistance to HIV infection.
...
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Rakai, Uganda
Understanding the factors that contribute to the transmission of human immunodeficiency virus (HIV) infection is of great importance for the development of preventive and therapeutic strategies. Evidence suggests that a number of host immunologic and virologic factors play critical roles in protection against sexually transmitted HIV infection in HIV-discordant partners. Among these, the antiviral role of CD8+ T cells in HIV-infected individuals has been extensively studied. At least two types of CD8+ T cell-mediated antiviral activities have been described in HIV infection. The first is a suppressive activity against HIV involving lysis of infected cells in an antigen-specific, HLA-restricted fashion, while the second mechanism inhibits viral replication via either cell- or soluble mediated factors in the absence of cell killing. It has been demonstrated that cytotoxic CD8+ T lymphocytes (CTL) are present in both cervical and peripheral blood mononuclear cells (PBMC) from a subpopulation of highly-HIV-exposed but persistently seronegative individuals. However, studies addressing the effect of non-cytotoxic soluble factor-mediated antiviral activity by CD8+ T cells in preventing seroconversion in HIV-discordant couples have been lacking. This study proposes to examine the role of CD8+ T cell-derived CC-chemokine activities and the copy numbers of one of the chemokine genes, CCL3L1, along with other host anti-HIV and virologic factors in resistance to HIV infection in persistently seronegative HIV-discordant partners of HIV infected individuals.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Group 1 (HIV concordant partners, n = 20 couples):
Group 2 (HIV-discordant partners, n = 20 couples):
Group 3 (HIV-uninfected partners, n = 10 couples):
Exclusion criteria
Inability or unwillingness to provide individual informed consent, on the part of either or both members of the couple.
Refusal of couples counseling on the part of one or both partners.
Severe illness in one or the other, and /or a hemoglobin value less than 8 g/dL.
Age less than 18. Children are not included in this study since it specifically focuses on sexual transmission of HIV in long term married couples.
Having had a blood transfusion within the last 60 days. Though individuals can be scheduled after this time period has passed.
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Virologic and Immunologic Factors Contributing to the Lack of HIV-1 Transmission in HIV-Discordant Couples in Rakai, Uganda
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03734393
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Birmingham, Alabama, United States
View Trial DetailsNCT06176859
ART, Acquired Immunodeficiency Syndrome
Durban, KwaZulu-Natal, South Africa
View Trial DetailsNCT06139354
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05911360
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Phoenix, Arizona, United States
View Trial Details